Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115193) titled 'A multicenter, observational, and retrospective study on the treatment patterns after first-line osimertinib treatment resistance of EGFR mutant NSCLC in the real world' on Dec. 23, 2025.
Study Type: Observational study
Study Design:
Cross-sectional
Primary Sponsor: Zhejiang Taizhou hospital
Condition:
Lung cancer
Recruitment Status: Not Recruiting
Phase: Retrospective study
Date of First Enrollment: 2025-03-22
Target Sample Size: Not applicable:500;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=269225
Published by HT Digital Content Services with...